|
|
News Breaks | | | | November 13, 2012 | | 16:06 EDT |  | LLY, INCY | Eli Lilly, Incyte announce additional Phase IIb baricitinib data
Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced 24-week results from the continuation of an ongoing Phase IIb study of baricitinib, an orally available janus kinase inhibitor, in patients with moderate-to-severe rheumatoid arthritis who had an inadequate response to treatment with methotrexate. Additionally, Magnetic Resonance Imaging technology was used in a sub-study to examine the effect of baricitinib on joint erosion and other markers of structural changes in and around the joint. Positive results of the placebo-controlled 12-week portion of the study were presented at the European League Against Rheumatism's Annual European Congress of Rheumatology in June. Patients taking baricitinib 4 mg or 8 mg once daily reported significant differences in ACR20, ACR50 and ACR70 responses compared with patients taking placebo. Data from the 12- to 24-week portion of the study, which did not include a placebo control, showed that patients who continued to receive 2 mg, 4 mg or 8 mg baricitinib once daily doses maintained or improved ACR20, ACR50 and ACR70 responses. The study also included a large sub-study of 154 patients using Magnetic Resonance Imaging to examine the effect of different doses of baricitinib on joint changes in a subgroup of patients with erosive RA and inadequate response to treatment with methotrexate. There was statistically significant improvement in both the Total Inflammation Score and the Total Joint Damage Score for both 4 mg and 8 mg baricitinib doses compared with placebo at 12 weeks. The effects persisted through 24 weeks. | |
|
News For LLY;INCY From The Last 14 Days Check below for free stories on LLY;INCY the last two weeks. |
|
|
| May 21, 2013 | | 07:24 EDT |  | LLY | Global Health Care to host a conference
 Subscribe for More Information | | | May 16, 2013 | | 08:55 EDT | | LLY | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information | | | May 14, 2013 | | 09:09 EDT | | LLY | Eli Lilly announces CEO John Lechleiter recovering from surgery
Subscribe for More Information | | | 07:24 EDT | | LLY | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. | | | May 10, 2013 | | 11:48 EDT |  | LLY | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information | | | 08:02 EDT | | LLY | Eli Lilly's Enzastaurin Phase III study did not meet primary endpoint
Eli Lilly announced Phase III clinical trial results from enzastaurin's PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma. The study failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of relapse following rituximab-based chemotherapy. There were no new safety findings, and the safety data were consistent with previously disclosed studies. Lilly will stop development of enzastaurin, which is expected to result in a second-quarter charge to R&D expense of approximately $30M. The company's previously-issued financial guidance for 2013 remains unchanged. | | | May 9, 2013 | | 11:01 EDT | | LLY | Sears Holdings names Jeff Balagna Chief Information Officer
Subscribe for More Information | |
|
|
|
|
|
|
